Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price fell 16.7% during mid-day trading on Tuesday . The company traded as low as C$0.10 and last traded at C$0.10. 236,500 shares were traded during trading, a decline of 15% from the average session volume of 278,294 shares. The stock had previously closed at C$0.12.
Hemostemix Trading Up 34.5 %
The stock has a market capitalization of C$16.99 million, a P/E ratio of -9.75 and a beta of 0.20. The firm’s fifty day moving average is C$0.09 and its 200-day moving average is C$0.07.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Articles
- Five stocks we like better than Hemostemix
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- The 3 Best Fintech Stocks to Buy Now
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- Using the MarketBeat Dividend Tax Calculator
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
